Gfr.alpha.1-ret specific agonists and methods therefor

C - Chemistry – Metallurgy – 12 – N

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C12N 15/18 (2006.01) A61K 31/7088 (2006.01) A61K 38/18 (2006.01) C07K 14/475 (2006.01) C12N 5/06 (2006.01) C12N 5/08 (2006.01) C12N 5/10 (2006.01) C12N 15/63 (2006.01)

Patent

CA 2396039

Chimeric GDNF family ligands which activate a GFR.alpha./RET are disclosed. Included are chimeras which activate GFR.alpha.1/RET but do not activate GFR.alpha.2-RET or GFR.alpha.3-RET. The chimeras are useful in providing trophic support to a mammalian cell or in producing differentiation of a mammalian cell, or both, particularly when the cell is in a patient suffering from various diseases, in particular Parkinson's Disease.

L'invention concerne des ligands chimères de la famille GDNF activant un GFR.alpha./RET. Elle englobe des chimères activant GRF.alpha.1/RET mais n'activant pas GFR.alpha.2-RET ou GRF.alpha.3-RET. Ces chimères sont utiles pour apporter un support trophique à une cellule mammifère ou pour produire une différenciation de cellules mammifères, ou les deux, en particulier quand la cellule appartient à un patient atteint de différentes maladies, en particulier, la maladie de Parkinson.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Gfr.alpha.1-ret specific agonists and methods therefor does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Gfr.alpha.1-ret specific agonists and methods therefor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Gfr.alpha.1-ret specific agonists and methods therefor will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1817802

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.